Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

PNOC023: Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults with Newly Diagnosed or Recurrent Diffuse Mid… Recruiting

2025-521180-13-00 Diffuse Midline Glioma (DMG), and Other Recurrent Prima 1 2026-03-04
A Phase III Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients with Recurrent Glioblastoma Recruiting

2025-521785-10-00 Glioblastoma 5 2026-03-04
A Long-Term Follow-up Study for Subjects Previously Treated with A Century Therapeutics Cellular Therapy Product Recruiting

2024-520222-11-00 Hematological or solid tumor malignancies or autoimmune 3 2026-03-03
A clinical study of new treatments for non-small cell lung cancer (MK-3475-01J) Recruiting

2025-521939-36-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 4 2026-03-03
PASSION (olaParib mAintenance in chemotherapy-Sensitive metaStatic pancreatIc adenOcarciNoma - mPDAC): a phase II, proof of principle, study Recruiting

2025-522530-31-01 Patients with metastatic PDAC, who have not progressed 4 2026-02-27
A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants … Recruiting

2024-519622-20-00 Advanced Solid Tumors Harboring RAS Mutation(S) 1 2026-02-27
A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor Recruiting

2025-522033-64-00 Myelofibrosis 1 2026-02-26
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms. Recruiting

2024-520353-21-00 Myeloproliferative Neoplasms 3 2026-02-24
First-in-Human trial of DS9051b in participants with advanced solid tumors Recruiting

2025-521886-28-00 Advanced or Metastatic Adrenocortical Carcinoma (ACC), 1 2026-02-19
PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST C… Recruiting

2024-520027-88-00 Patients with hormone receptor-positive (HR+) breast ca 4 2026-02-12
Testosterone intake in supportive care patients: impact on quality of life. Recruiting

2025-522023-10-00 Androgen deficiency, palliative care 4 2026-02-11
A clinical study of new treatments given with enfortumab vedotin and pembrolizumab in people with urothelial cancer (MK-3475-04D) Recruiting

2025-522253-19-00 Urothelial carcinoma 9 2026-02-11
A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III me… Recruiting

2025-521919-39-00 Resected stage IIB, IIC, or III melanoma requiring adju 3 2026-02-10
NON-IV: Neo-adjuvant peritumOral immuNotherapy In Vulvar cancer Recruiting

2025-520712-34-00 Vulvar Cancer 3 2026-02-04
A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) Recruiting

2025-522398-12-00 Locally advanced or metastatic NSCLC 3 2026-01-30
A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting

2025-522767-15-00 Acute Myeloid Leukemia 5 2026-01-27
A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting

2025-521514-26-00 Persistent, Recurrent, or Newly Diagnosed Metastatic Ce 5 2026-01-26
A Phase 2 Study of PTX-100 Monotherapy in Patients with r/r CTCL Recruiting

2025-521852-45-00 Cutaneous T-Cell Lymphoma 4 2026-01-22
A Phase 1/2 First-Time-in-Human study of GSK5458514 administered alone or in combination with other anti-cancer agents in participants with … Recruiting

2025-521581-10-00 Neoplasms, Prostate 7 2026-01-16
Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting

2024-520433-76-00 Newly Diagnosed Multiple Myeloma 4 2026-01-08
A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01] Recruiting

2022-501607-27-00 Relapsed or refractory B-cell Non-Hodgkin lymphoma 7 2026-01-06
LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and… Recruiting

2023-508995-12-01 Recurrent or metastatic non-small cell lung cancer (NSC 4 2025-12-24
A study to compare Efficacy, Safety and How the Body Absorbs, Distributes, and Eliminates of Subcutaneous CT-P44 and Darzalex Faspro in Comb… Recruiting

2024-518588-36-00 Refractory or Relapsed Multiple Myeloma 5 2025-12-24
A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting

2023-507525-42-00 Endometrial cancer 5 2025-12-23